Preliminary observations on carcass traits and meat yield of five types of Brahman-influenced grass-fed bulls

Benefiting from interventions of the savanna ecosystem, breeders in Los Llanos of Apure State (Venezuela) are exploring the opportunity to improve cattle genetics by implementing crossbreeding programs.  Fifty yearling bulls of five types of Brahman influence [ST-Brahman (n = 10), F1 Angus x Brahman (F1-Angus; n = 10), F1 Chianina x Brahman (F1-Chianina; n = 10), F1 Romosinuano x Brahman (F1-Romosinuano; n = 10), and F1 Simmental x Brahman (F1-Simmental; n = 10)] were selected to be compared in carcass performance (linear measurements, quality and quantity indicators, Venezuelan and U.S. grades, and cutability) at a desirable conformation endpoint with a suitable market weight of 480 kg.  Shorter ST-Brahman carcasses exhibited the most abundant finish, significantly different from the longer F1-Simmental and F1-Romosinuano counterparts.  All carcasses fell into the A youngest maturity and were eligible for the USDA "Bullock “class designation; 62% reached the top Venezuelan quality grade, 96% graded US Standard and 64% reached the US yield grade 1, indicating superior cutability. Significant differences in yield of individual cuts (ribeye + strip loin, and cuts from the round) were detected between F1-Romosinuano and St-Brahman, F1-Angus and F1-Chianina counterparts.  F1-Chianina bulls had slight but significant advantages in yield of high-valued boneless cuts as compared to those of F1-Romosinuano and F1-Simmental counterparts. Conversely, F1-Romosinuano outperformed F1-Chianina in 1.73 percentage points of medium-valued boneless cuts (P < 0.05).  Under the sample selection criteria and harvest endpoint, slight changes in carcass performance can be expected from crossbreeding.Con intervenciones del ecosistema sabana y aplicando un manejo adecuado de los pastos, ganaderos de Los Llanos del Estado Apure (Venezuela) estan explorando mejorar la genética del ganado con programas de cruzamiento.  Cincuenta machos enteros añosos de cinco tipos raciales con influencia Brahman [Brahman puro (n = 10), F1 Angus x Brahman (F1-Angus; n = 10), F1 Chianina x Brahman (F1-Chianina; n = 10), F1 Romosinuano x Brahman (F1-Romosinuano; n = 10) y F1 Simmental x Brahman (F1-Simmental; n = 10)] se compararon en desempeño de la canal (mediciones lineales, indicadores de calidad y cantidad, categorías de clasificación y rendimiento carnicero) a un punto final de conformación deseable con un peso corporal aproximado de 480 kg.  Canales más cortas de Brahman puros exhibieron acabado más abundante, diferente (P<0.05) de las contrapartes más largas F1-Simmental y F1-Romosinuano.  Todas las canales cayeron en la madurez más joven (A) y fueron elegibles para la designación de clase "Bullock" del USDA; el 62% alcanzó el grado de calidad superior venezolano (categoría A), el 96% calificó en el grado de calidad Standard y el 64% alcanzó el grado máximo de rendimiento carnicero (grado 1 USDA).  Los toretes F1-Chianina tuvieron ventajas leves pero significativas en rendimiento en cortes deshuesados de alto valor, en comparación con los de F1-Romosinuano y F1-Simmental.  Por el contrario, F1-Romosinuano superó a F1-Chianina en 1,73 puntos porcentuales de cortes deshuesados de valor medio (P <0.05).  Bajo los criterios de selección de la muestra y el punto final de la cosecha, no se pueden esperar grandes cambios en el rendimiento carnicero a partir del cruzamiento.Com o uso de tecnologias em um ecossistema de savana e aplicando um manejo adequado das pastagens, os criadores de Los Llanos do Estado de Apure (Venezuela) estão tentando melhorar a genética do gado através da utilização de programas de cruzamento.  Cinquenta bovinos machos não castrados, com peso de abate de ~480 kg, de cinco cruzamentos com Brahman [Brahman puro (n = 10), F1 Angus x Brahman (F1-Angus; n = 10), F1 Chianina x Brahman (F1-Chianina; n = 10), F1 Romosinuano x Brahman (F1-Romosinuano; n = 10) e F1 Simental x Brahman (F1-Simental; n = 10)], foram comparados quanto às características (medidas lineares, indicadores de qualidade e quantidade e rendimento de desossa) y tipificacao de carcaça.    Carcaças de Brahman puros apresentaram maior cobertura de gordura do que carcaças de animais F1-Simmental e F1-Romosinuano (P<0.05).  Todas as carcaças foram com maturidade “A” (jovem / Bullock), sendo que 96% se qualificaram no grau de qualidade USDA “Standard” e 64% alcançaram o grau máximo de rendimento de desossa (grau 1).  Pelo padrão venezuelano, 62% das carcaças alcançaram o grau de qualidade superior (categoria A).  Diferenças significativas foram detectadas no rendimento de cortes individuais (filé de costela e contrafilé e cortes do coxão) entre carcaças de F1-Romosinuano e F1-Simental e F1-Angus e F1-Chianina. Carcaças de F1-Chianina apresentaram maiores rendimentos em cortes desossados de alto valor em comparação com F1-Romosinuano e F1-Simmental.  Carcaças de F1-Romosinuano tiveram 1,73 pontos percentuais a mais de rendimento em cortes desossados de valor intermediário, que carcaças de F1-Chianina (P <0,05). Segundo os critérios de seleção da amostra e o ponto final de abate, não se podem esperar grandes mudanças na qualidade e rendimento das carcaças de diferentes cruzamentos. &nbsp

SEOM clinical guideline for the management of cutaneous melanoma (2020)

Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I-III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

PURPOSE In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes. PATIENTS AND METHODS Patients with previously untreated unresectable stage III or stage IV melanoma were randomly assigned 1:1:1 to receive nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks (four doses) followed by nivolumab 3 mg/kg once every 2 weeks (n = 314), nivolumab 3 mg/kg once every 2 weeks (n = 316), or ipilimumab 3 mg/kg once every 3 weeks (four doses; n = 315). Coprimary end points were progression-free survival and overall survival (OS) with nivolumab plus ipilimumab or nivolumab versus ipilimumab. Secondary end points included objective response rate, descriptive efficacy assessments of nivolumab plus ipilimumab versus nivolumab alone, and safety. Melanoma-specific survival (MSS; descriptive analysis), which excludes deaths unrelated to melanoma, was also evaluated. RESULTS Median OS (minimum follow-up, 6.5 years) was 72.1, 36.9, and 19.9 months in the combination, nivolumab, and ipilimumab groups, respectively. Median MSS was not reached, 58.7, and 21.9 months, respectively; 6.5-year OS rates were 57%, 43%, and 25% in patients with BRAF-mutant tumors and 46%, 42%, and 22% in those with BRAF–wild-type tumors, respectively. In patients who discontinued treatment, the median treatment-free interval was 27.6, 2.3, and 1.9 months, respectively. Since the 5-year analysis, no new safety signals were observed. CONCLUSION These 6.5-year CheckMate 067 results, which include the longest median OS in a phase III melanoma trial reported to date and the first report of MSS, showed durable, improved clinical outcomes with nivolumab plus ipilimumab or nivolumab versus ipilimumab in patients with advanced melanoma and, in descriptive analyses, with the combination over nivolumab monotherapy

Effects of postmortem calcium chloride injection on meat palatability traits of strip loin steaks from cattle supplemented with or without zilpaterol hydrochloride

An experiment was conducted to determine the effects of zilpaterol hydrochloride mM supplementation (ZH; 8.3 mg/kg on a DM basis for 20 d) and calcium chloride injection [CaCl2, 200 at 5% (wt/wt) at 72 h postmortem] on palatability traits of beef (Bos taurus) strip loin steaks. Select (USDA) strip loins were obtained from control (no ZH = 19) and ZH-supplemented carcasses (n = 20). Right and left sides were selected alternatively to serve as a control (no INJ) or CaCl2-injected (INJ) and stored at 4 degrees C Before injecting the subprimals (72 h postmortem), 2 steaks were cut for proximate, sarcomere length, and myofibrillar fragmentation index (MFI) analyses. At 7 d postmortem each strip loin was portioned into steaks, vacuum packaged, and aged for the appropriate period for Warner-Bratzler shear force (WBSF; 7, 14, 21, and 28 d postmortem), trained sensory analysis (14 and 21 d postmortem), purge loss (7 d), and MFI (3, 7, 14, 21, and 28 d postmortem). Results indicated steaks from both ZH supplementation and INJ had reduced WBSF values as days of postmortem aging increased. The WBSF values of ZH steaks were greater (P 0.05) due to ZH at 14, 21, or 28 d or due to INJ at any aging period. Trained panelists rated tenderness less in ZH steaks than steaks with no ZH at 14 d and 21 d. However, INJ improved (P < 0.05) the tenderness ratings and flavor intensity of the trained panelists, compared with their non-injected cohorts at 21 d. Zilpaterol hydrochloride supplementation reduced (P < 0.05) MFI values, but INJ resulted in greater (P < 0.05) MFI values compared with no INJ. Subprimals from ZH and INJ showed greater purge loss (P < 0.05). Although no interactions were found with ZH and CaCl2, injecting USDA Select strip loins from ZH-fed cattle can help reduce the normal WBSF variation as it does in steaks from non-ZH-fed cattle.90103584359

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

945 patients with inoperable stage III or stage IV melanoma were randomised to ipilimumab plus nivolumab (ipi/nivo)(314), nivolumab (nivo) (316) or ipilimumab (Ipilimumab) (315). The minimum follow up from randomisation of the last patient was 60 months. Objective responses were seen in 58% of Ipilimumab/nivo, 45% of nivo and 19% of Ipilimumab patients. Complete responses were seen in 22% (Ipilimumab/nivo), 19% (nivo) and 6% (Ipi) patients. Overall survival (OS) at five years was 52% (Ipilimumab/nivo), 44% (nivo) and 26% (Ipi). In patients with and without bras mutations the OS at five years was 60 & 48% (Ipilimumab/nivo), 46 & 43% (nivo) and 30 & 25% (Ipi) respectively. OS curves were flat beyond three years indicating that these treatments lead to sustained long term survival of these patients

Effect of Immunosuppressive Treatments on Kidney Outcomes After Gross Hematuria-Related Acute Kidney Injury in Older Patients With IgA Nephropathy

Macroscopic hematuria (MH) bouts, frequently accompanied by acute kidney injury (AKI-MH) are one of the most common presentations of IgA nephropathy (IgAN) in the elderly. Immunosuppressive therapies are used in clinical practice; however, no studies have analyzed their efficacy on kidney outcomes. This is a retrospective, multicenter study of a cohort of patients aged ≥50 years with biopsy-proven IgAN presenting with AKI-MH. Outcomes were complete, partial, or no recovery of kidney function at 1 year after AKI-MH, and kidney survival at 1, 2, and 5 years. Propensity score matching (PSM) analysis was applied to balance baseline differences between patients treated with immunosuppression and those not treated with immunosuppression. The study group consisted of 91 patients with a mean age of 65 ± 15 years, with a mean follow-up of 59 ± 36 months. Intratubular red blood cell (RBC) casts and acute tubular necrosis were found in all kidney biopsies. The frequency of endocapillary hypercellularity and crescents were low. Immunosuppressive therapies (corticosteroids alone or combined with mycophenolate mofetil or cyclophosphamide) were prescribed in 52 (57%) patients, whereas 39 (43%) received conservative treatment. There were no significant differences in the proportion of patients with complete, partial, or no recovery of kidney function at 1 year between patients treated with immunosuppression and those not treated with immunosuppression (29% vs. 36%, 30.8% vs. 20.5% and 40.4 % vs. 43.6%, respectively). Kidney survival at 1, 3, and 5 years was similar among treated and untreated patients (85% vs. 81%, 77% vs. 76% and 72% vs. 66%, respectively). Despite the PSM analysis, no significant differences were observed in kidney survival between the two groups. Fourteen patients (27%) treated with immunosuppression had serious adverse events. Conclusions: Immunosuppressive treatments do not modify the unfavorable prognosis of patients with IgAN who are aged ≥50 years presenting with AKI-MH, and are frequently associated with severe complications

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts

Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin (Cb) to anthracycline/taxane chemotherapy improves pathological complete response (pCR) in triple negative breast cancer (TNBC). Effectiveness of anthracycline-free, platinum combinations in TNBC is not well known. Here we report efficacy of NA carboplatin + docetaxel (CbD) in TNBC

Frequency and characteristics of familial melanoma in Spain: The FAM-GEM-1 Study

Similar to that observed in other countries, familial melanoma accounts for 6.6% of melanoma diagnoses in Spain. Although no differences in the multivariate analysis were found, some better prognosis factors, such as Breslow index, seem more frequent in familial melanoma, which reflect a better early detection marker and/or a different biological behavior

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

This is the three year update of a randomised phase III trial in patients with locally advanced inoperable stage III or stage IV melanoma. 1296 patients were radomised to receive either ipilimumab (Ipi), nivolumab (Nivo) or both antibodies (Ipi+Nivo). Complete responses were seen in 5, 16 & 19% of patients in the Ipi, Nivo and Ipi+Nivo groups respectively. Partial responses were seen in 14, 28 & 29% of patients respectively. With a minimum follow up of 28 months 3 year overall survivals were 32, 52 & 58% in the Ipi, Nivo & Ipi+Nivo respectively. In patients with braf mutations the three year survivals were 37, 56 & 68% in the three groups. This compares with a three year survival of 44% in the dabrafenib plus trametinib arm of the COMBI-D trial (J. Clin. Oncol. 2017 Dob: 10.1200/JCO.2017.74.1025). These data represent practice changing data for oncologist who treat melanoma and life changing treatment for patients with metastatic melanoma